Patisiran, inotersen aid hereditary transthyretin amyloidosis

July 6, 2018

(HealthDay)—For patients with hereditary transthyretin amyloidosis with polyneuropathy, an investigational RNA interference therapeutic agent (patisiran) and a 2'-O-methoxyethyl-modified antisense oligonucleotide (inotersen), which inhibits hepatic production of transthyretin, improve clinical manifestations of disease, according to two studies published in the July 5 issue of the New England Journal of Medicine.

David Adams, M.D., Ph.D., from the Université Paris-Sud, and colleagues conducted a phase 3 trial involving patients with hereditary transthyretin amyloidosis with polyneuropathy receiving either patisiran (148 patients) or (77 patients). The researchers found that the least-squares mean change from baseline in the modified Neuropathy Impairment Score+7 (mNIS+7) was −6.0 ± 1.7 versus 28.0 ± 2.6 in the patisiran versus the placebo group (difference, −34.0 points) at 18 months. The least-squares mean change from baseline in the Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) questionnaire was −6.7 ± 1.8 versus 14.4 ± 2.7 (difference, −21.1 points) at 18 months.

Merrill D. Benson, M.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a randomized trial involving adults with stage 1 or 2 hereditary transthyretin amyloidosis with polyneuropathy. Patients were randomized to inotersen (112 patients) or placebo (60 patients). The researchers found that the difference in the least-squares mean change from baseline to week 66 favored inotersen versus placebo (−19.7 points for the mNIS+7 and −11.7 points for the Norfolk QOL-DN score).

"Inotersen improved the course of neurologic disease and quality of life in with hereditary transthyretin amyloidosis," Bensen and colleagues write.

The Adams study was supported by Alnylam Pharmaceuticals; the Benson study was funded by Ionis Pharmaceuticals.

Explore further: Tezacaftor-ivacaftor, ivacaftor alone effective in CF

More information: Abstract/Full Text - Adams (subscription or payment may be required)
Abstract/Full Text - Benson (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Tezacaftor-ivacaftor, ivacaftor alone effective in CF

November 7, 2017
(HealthDay)—Tezacaftor-ivacaftor or ivacaftor alone is effective for patients with cystic fibrosis who are heterozygous for the Phe508del deletion, and tezacaftor-ivacaftor is effective for patients who are homozygous for ...

Distal bicep tendon rip tied to transthyretin amyloidosis

September 13, 2017
(HealthDay)—Rupture of the distal biceps tendon (RBT) in a patient with heart failure with preserved ejection fraction should raise suspicion for wild-type transthyretin amyloidosis (ATTRwt), according to a research letter ...

Lumacaftor, ivacaftor linked to improved lung function in CF

June 12, 2017
(HealthDay)—For patients aged 6 to 11 years with cystic fibrosis homozygous for F508del-cystic fibrosis transmembrane conductance regulator (CFTR), lumacaftor and ivacaftor treatment is associated with significant improvement ...

Evolocumab doesn't affect cognition when added to statins

August 17, 2017
(HealthDay)—There is no significant difference in cognitive function for patients treated with evolocumab or placebo added to statin therapy, according to a study published in the Aug. 17 issue of the New England Journal ...

C1 inhibitor use reduces attacks in hereditary angioedema

March 23, 2017
(HealthDay)—Prophylactic use of the subcutaneous C1 inhibitor CSL830 is associated with a reduction in the frequency of acute attacks in patients with hereditary angioedema, according to a study published in the March 23 ...

Dupilumab effective in atopic dermatitis

October 4, 2016
(HealthDay)—Dupilumab is effective for patients with moderate-to-severe atopic dermatitis that is inadequately controlled by topical treatment, according to a study published online Oct. 1 in the New England Journal of ...

Recommended for you

New hope for cystic fibrosis

October 19, 2018
A new triple-combination drug treatment being trialled at the Mater Hospital in Brisbane could increase the life expectancy of patients with cystic fibrosis.

Bug guts shed light on Central America Chagas disease

October 18, 2018
In Central America, Chagas disease, or American trypanosomiasis, is spread by the "kissing bug" Triatoma dimidiata. By collecting DNA from the guts of these bugs, researchers reporting in PLOS Neglected Tropical Diseases ...

Rapid genomic sequencing of Lassa virus in Nigeria enabled real-time response to 2018 outbreak

October 18, 2018
Mounting a collaborative, real-time response to a Lassa fever outbreak in early 2018, doctors and scientists in Nigeria teamed up with researchers at Broad Institute of MIT and Harvard and colleagues to rapidly sequence the ...

Researchers cure drug-resistant infections without antibiotics

October 17, 2018
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria ...

Infectious disease consultation significantly reduces mortality of patients with bloodstream yeast infections

October 17, 2018
In a retrospective cohort study conducted at the University of Alabama at Birmingham Division of Infectious Diseases, patients with candidemia—a yeast infection in the bloodstream—had more positive outcomes as they relate ...

How drug resistant TB evolved and spread globally

October 17, 2018
The most common form of Mycobacterium tuberculosis (TB) originated in Europe and spread to Asia, Africa and the Americas with European explorers and colonialists, reveals a new study led by UCL and the Norwegian Institute ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.